Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Total revenue		$ 388,819	$ 83,177	$ 429,553
Operating costs and expenses
Research and development	$ 3,891,500	1,800,100	5,410,459	2,649,618
Research and Development - Milestone expense for Patagonia Pharmaceuticals LLC	4,000,000		4,000,000
Selling, general and administrative	1,512,343	1,556,012	3,214,738	2,621,401
Total operating expenses	9,403,843	3,356,112	12,625,197	5,271,019
Loss from operations	(9,403,843)	(2,967,293)	(12,542,020)	(4,841,466)
Other income (expense)
Interest expense	(42,077)		(96,328)
Other income			75,000
Forgiveness of PPP loan			37,772
(Loss) gain on foreign currency exchange	(50,076)	1,090	(43,814)	1,003
Total other income (expense)	(92,153)	1,090	(27,370)	1,003
Net loss	(9,495,996)	(2,966,203)	(12,569,390)	(4,840,463)
Dividends on Series A preferred stock		(36,286)		(72,173)
Net loss attributable to common stockholders	$ (9,495,996)	$ (3,002,489)	$ (12,569,390)	$ (4,912,636)
Basic net loss per share attributable to common stockholders	$ (0.15)	$ (0.08)	$ (0.20)	$ (0.14)
Diluted net loss per share attributable to common stockholders	$ (0.15)	$ (0.08)	$ (0.20)	$ (0.14)
Basic weighted average number of shares outstanding	63,731,582	36,659,685	63,684,906	35,872,780
Diluted weighted average number of shares outstanding	63,731,582	36,659,685	63,684,906	35,872,780
Grant revenue
Total revenue		$ 134,927	$ 83,177	$ 175,661
Milestone revenue
Total revenue		$ 253,892		$ 253,892